• We need to be more than a patent registry factory

    'Patent or perish'is the slogan of Ragunath Mashelkar, head of India's greatest freely financed scientific agency. In the last decade he's turned the 40 or so laboratories under his get a handle on in to a patent factory. "Our labs receive more patents in the United Claims than all Indian inventors mixed," boasts Mashelkar, who blows the Council of Medical and Industrial Study (CSIR). "To be recognized, you will need a account of patents."

     

    But not everybody is free innovation impressed. Experts are accusing the council of squandering individuals'income by patenting hundreds of spurious inventions which can be never exploited.

     

    The approach of the CSIR has been to file a patent on any new discovering that matches the criteria, whether or not the agency desires to commercialize it, claims R. K. Gupta, the CSIR's main of patents. That technique has certainly succeeded with regards to quantity. Between 2002 and 2006, the CSIR was awarded 542 US patents — more compared to the overall quantity granted to its counterparts in France, China and Germany combined.

     

    A lot of money is heading down the drain.

     

    But according to Suresh Chandran, who handled biotech patents in India before getting certification supervisor for ES Cell Global in Singapore, "A lot of the patents aren't actually value the paper they are printed on." He highlights that each US patent expenses the CSIR US$25,000 for filing and $4,000 a year for maintenance. "Maybe it is a passing period, but I can let you know that we waste a lot on this task," he says.

     

    An example distributed by critics is just a cow urine remove that the CSIR patented in the United States in 2002, declaring so it improved the activity of antibiotics. The declare is yet to be supported with a peer-reviewed publication and the CSIR admits that no medicine organization indicates interest. "We'd an excellent laugh when we study about any of it, and that was it," says a spokesman for a leading drug business in New Delhi, who asked to not be named.

     

    ADVERTISEMENT

     

    Masheklar disputes that the patents are a spend of money, pointing out that the cluster of three US patents on a possible anticancer molecule has been registered out to an Indian entrepreneur in the United States for approximately $100,000. Given that just about 3% of US patents are ever licensed, it is too soon for the CSIR to anticipate major results, he says.

     

    Experts table that even though strategy of patenting every thing has generated understanding among scientists of the possible worth of their discoveries, it is time to ensure that patents develop services and products and wealth, not merely statistics. A. V. Rama Rao, former director of the CSIR Indian Institute of Compound Engineering in Hyderabad, wants the CSIR to setup an unbiased department to decide which developments are price patent applications. "A lot of money is heading down the drain in the name of patents," he says.


  • Commentaires

    Aucun commentaire pour le moment

    Suivre le flux RSS des commentaires


    Ajouter un commentaire

    Nom / Pseudo :

    E-mail (facultatif) :

    Site Web (facultatif) :

    Commentaire :